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Diabetic neuropathy denotes to a group of nerve disorders caused by diabetes. It 
may occur in both type 1 and type 2 diabetes patients. Mitochondria are essential for 
energy production as well as intermediary metabolism and equally important in the 
action of insulin on its targeted tissue. Recently, mitochondrial dysfunctions have been 
recognized as a cause of diabetes. Hyperglycemia enhances the activity of mitochondrial 
electron transport chain, leading to mitochondrial hyperpolarisation and elevates the 
reactive oxygen species (ROS) production. Increased electron availability causes partial 
reduction of oxygen to superoxide in the proximal electron transport chain which 
subsequently induces neurodegeneration in diabetes. Currently there is no satisfactory 
pharmacotherapy for painful diabetic neuropathy. This review summarizes 
mitochondrial role in type 2 diabetic neuropathy, diagnostic challenges, general 
treatments and benefits of alternative approach for effective management. 
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INTRODUCTION 
Diabetes is a chronic disease resulting in 
high blood sugar levels in the blood. 
Diabetic neuropathy is common 
complication in both type 1 and 2 diabetes.  
Its prevalence was estimated that 60-70% of 
people with diabetes have various form of 
neuropathy complication. Patients can 
develop nerve problem at any time but 
danger rises with age and longer duration 
of diabetes (Feldman et al., 2001; Polydefkis 
et al., 2003; Dyck et al., 1993). Defective 
pancreatic insulin secretion and defective 
insulin action represent the principal 
pathophysiological abnormalities leading to 
increase blood glucose levels (Kahn and 
Rossetti, 1998). The reduced synthesis of 
adenosine triphosphate (ATP) was found to 
be involved in the impaired defective 
secretion of insulin from pancreatic beta 
cells. The impairment of mitochondrial 
function reported to have basic relationship 
in the development of type 2 diabetes and 
its associated complication including 
neuropathy (Petersen et al., 2004). Recently, 
pathogenetic evidence suggests that 
diabetic neuropathy is marked by 
degeneration of dorsal root ganglion (DRG) 
neurons in peripheral nerves and that DRG 
mitochondrial are particularly affected 
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(Beal, 2005). Wily and his co-workers 
demonstrated that isolated adult sensory 
neurons from streptozotocin (STZ) induced 
diabetes rats exhibit the depolarization of 
mitochondrial inner membrane (Russell et 
al., 2006). The disturbances in mitochondrial 
function have been linked to 
neurodegenerative disease in the central 
and peripheral nervous system 
(Zherebitskaya et al., 2009) and 
mitochondrial genes are also reasonable 
causative agents of type 2 diabetes and its 
associated complication (Lowell and 
Shulman, 2005; Ohkubo et al., 2001). But 
overall percentage of mitochondrial 
mutation in type 2 diabetes with 
neuropathy complication is currently 
unknown. Since developing better novel 
preventing strategies, diagnostic procedure 
and treatments for type 2 diabetic with 
neuropathy is matter of great urgent to 
provide patients in our society. So it is 
essential to understand the pathogenesis of 
type 2 diabetes and its neuropathy 
complication. At present conventional 
medicine can proffer several help to reduce 
the neuropathy pain but significant few 
side effects and do not address the 
underlying pathologies (Kathleen, 2006; 
Andrew and Boulton, 2005). There are 
certain alternative remedy, natural 
supplements, physical activity, relaxation 
technique that are all may play a role in 
reducing the risk and improvement in 
neurological function, stimulate the 
mitochondrial biogenesis and reducing 
severity of diabetic neuropathy (Kathleen, 
2006; Ihara et al., 1989a; Bresolin et al., 
1989b; Bendahan et al., 1992; Nishikawa et 
al., 1989b; Broedl and Goke, 2006; Lynda, 
2005; Toledo et al., 2007; Trenell et al., 2008, 
Morrato et al., 2007). Hence this review 
article will highlight diabetic neuropathy 
causes, role of mitochondria in beta cell 
secretion, oxidative stress, mitochondrial 
DNA defect, diagnostic challenges, it will 
also briefly address certain aspects of 
diabetic neuropathy therapy and effective 
management practices.  
  
CAUSES AND TYPES OF NEUROPATHY 
DIABETES  
The high glucose levels are known to harm 
the nerves ability to transmit signals and 
damage the blood vessels that carry 
oxygen, nutrients to the nerves which result 
nerve damage (Said, 2007). Damaged nerve 
cannot carry messages between the brain 
and other parts of the body. Neuropathy 
complications may produce a wide range of 
symptoms and affect badly to the person, 
these tend to be gentle at first and get worse 
over time (Boulton et al., 2005). Several 
combination of factors contributes to cause 
the neuropathy diabetes. Inflammation in 
the nerves caused by an autoimmune 
response, genetic factors, alcohol abuse and 
smoking, which damage both nerves and 
blood vessels and significantly increase the 
risk of infections (Said, 2007). Another 
cause of nerve problem is due to continues 
use of drug for other major disease, for 
example drugs that lower the cholesterol 
may cause neuropathy 
(www.realfoodnutrients.com). Radiation 
treatment and chemotherapy drugs often 
cause neuropathy complication problem. 
However, mitochondrial dysfunctions have 
appeared as a common cause of many types 
of neuropathy diabetes. Additionally, a 
number of mutations that affect 
mitochondrial function are now thought to 
be accountable for several forms of 
inherited neuropathies (Suter and Scherer, 
2003; Suzuki et al., 2002). The hypothesized 
with the intention of lipid peroxidation 
under hyperglycemic condition also causes 
mitochondrial mutation that increase 
oxygen radicals, causing further damage to 
the mitochondrial respiratory chain, 
ultimately resulting in sensory neuropathy 
(Suzuki et al., 2002).   
 
Diabetic neuropathy types include 
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peripheral neuropathy, autonomic 
neuropathy, proximal neuropathy and focal 
neuropathy (Boulton et al., 2005). Peripheral 
neuropathy causes pain, numbness, tingling 
in the extremities and slow nerve 
conduction. Autonomic neuropathy may 
alter the digestion, bowel and bladder 
function, sexual response and perspiration, 
it can also affect the nerve that serve the 
heart and control blood pressure (Said, 
2007). Proximal neuropathy causes pain in 
the hips or buttocks and leads to weakness 
in the legs. Focal neuropathy results in the 
sudden weakness in a group of nerves, 
causing muscle weakness or pain 
(http://diabetes.webmd.com/peripheral-
neuropathy-risk-factors-symptoms).  
 
MITOCHONDRIA FUNCTION AND β -
CELL SECRETION  
In pancreatic β-cells, the ATP/ADP ratio 
determines the opening probability of the 
KATP channel involved in insulin secretion. 
Changes in this ratio cause mitochondrial 
dysfunction and affect the setting of glucose 
stimulated insulin secreted (GSIS) in 
response (Lowell and Shulman, 2005). 
When the glucose transported across the 
cellular membrane by glucose transporters 
(GLUT-1), glycolysis transforms to 
pyruvate, of which more than 90% is 
shuttled into the mitochondria. The ratio of 
ATP/ADP increases as processing of the 
glucose through glycolysis, TCA cycle and 
increases in OXPHOS (Marmol et al., 2009; 
Paradies et al., 2009). This increase in 
ATP/ADP ratio causes the ATP-sensitive 
K+ channels to close, causing depolarization 
of voltage-sensitive Ca2+ channel, triggering 
the exocytosis of insulin secretory vesicles 
(Paradies et al., 2009). The importance of 
OXPHOS in GSIS has been demonstrated 
by several in vitro studies. Specific 
inhibitors of the complexes of 
mitochondrial respiratory chain have found 
to be inhibiting the insulin release from 
pancreatic islet cells (Marmol et al., 2009). 
Cells lacking mitochondrial DNA also lose 
their ability to progressive enhancement of 
insulin secretion by glucose stimulation. 
These cells depleted of mitochondrial DNA 
have unequal changes in the nuclear to 
mitochondrial composition of electron 
transport complexes and a loss of 
respiratory efficiency, relying on glycolysis 
for ATP production. Repopulation of cells 
lacking mitochondrial DNA cells with 
foreign mitochondrial DNA restores the 
property of GSIS (Maechler et al., 2010). 
This confirms the mitochondrial DNA and 
the mitochondrial respiratory function are 
necessary for GSIS and plays an important 
role in insulin secretion.  
 
MITOCHONDRIAL OXIDATIVE 
STRESS 
Hyperglycemia resulting from uncontrolled 
glucose regulation is generally recognized 
as the fundamental relation between 
diabetes and its complication (Rolo and 
Palmeira, 2006). Four cellular pathway 
contributors to hyperglycemia induced cell 
damage: increased polyol pathway flux, 
increases advanced glycation end product, 
activation of protein kinase C and 
hexosamine pathways (Li et al., 2009; Li et 
al., 2008; Rola and Palmeira, 2006; 
Leinninger et al., 2006; Dimauro, 2007). 
Inhibition of any single pathway has not 
been shown to halt the progression of 
neuropathy diabetes. Recent evidence 
indicates that all of the pathways result 
from a common origin oxidative stress 
(increases cellular ROS).  Oxidative stress is 
caused by an imbalance between the 
production of ROS and a biological system, 
ability to readily detoxify the reactive 
intermediates.  Cell produces ROS during 
normal metabolic flux via the 
mitochondrial electron transport chain (Li et 
al., 2008). ROS are detoxified by cellular 
antioxidant. Hyperglycemia can lead to 
increase in a surplus of NADH, FADH2 that 
then increases the flux trough the 
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mitochondrial electron transport chain.  
Subsequently, there is an increase of 
ATP/ADP ratio, hyperpolarization of the 
mitochondrial membrane potential. This 
high electrochemical likely difference 
trough generate by the proton gradient 
leads to partial inhibition of the electron 
transport in complex III, ensuing in an 
accumulation of electron to coenzyme Q. In 
turn, this drives partial reduction of O2 to 
generate the free radical anion superoxide 
(Leinninger et al., 2006). High glucose 
stimulation increased ROS these induced 
the damage impairs nerve function and 
resulting in peripheral, autonomic nervous 
system injury and the symptoms of 
neuropathy diabetes. Recent evidence 
showed that the brain may also endure 
from the incorrect resistances anti-oxidative 
stress. Oxidative stress corresponds to an 
important leads to the damage of neuronal 
along with vascular cells in central nervous 
system (Feldman, 2003). DRG neurons are 
distinctively vulnerable to damage because 
they have long and mitochondria rich axons 
that straight access the nerve blood supply. 
As a result, axonal mitochondria are 
sensitively exposes to the hyperglycemic 
environment and as the sites of increased 
ROS production, are early targets of 
oxidative stress (Leinninger et al., 2006; 
Dimauro, 2007). Hyperglycemia induced 
oxidative stress in mitochondria, which 
leads to diabetes and its complication.  
 
SIGNIFICANT OF MITOCHONDRIAL 
DNA  
Mitochondrial DNA is the only constitutive 
extra chromosomal DNA within cells. It is 
very small genome consists of multicopy 
and circular double standard DNA 
molecules (16,569 bp in human), which 
encodes 37 genes, of the 37 gene,  22 tRNA 
genes and 2rRNA genes required for 
mitochondrial protein synthesis, 13 
polypeptide genes, all of which encode 
essential compound of OXPHOS (Craven et 
al., 2011). Defects of the mitochondrial 
genome take the form of point mutations 
and deletions, these different mutations 
have been associated with many diseases. 
Mitochondrial DNA is highly vulnerable to 
oxidative damage by virtue of its close 
proximity to ROS production and lack of 
protective DNA binding protein such as 
histones, limited DNA repair mechanism 
(Leinninger et al., 2006).  Oxidative damage 
to mitochondrial DNA by ROS was 
reported to lead DNA strand breaks and 
the occurrence of somatic mitochondrial 
DNA mutation. Accumulation of these 
mitochondrial DNA mutations may result 
in dysfunction of the respiratory chain, 
leading to ROS production in mitochondria 
and subsequent accumulation of more 
mitochondrial DNA mutation. This vicious 
cycle may account for an increase in 
oxidative damage during hyperglycemia. 
Consequently, mitochondrial DNA is more 
prone to oxidative damage and possibly 
contributed to neuropathy diabetes 
(Schapira, 1998).  A few study is know 
about mitochondrial DNA integrity in the 
nerves of individual with diabetes (Rasmus 
et al., 2009; Knott et al., 2009; Ferrari et al., 
2011; Cassidy Stone et al., 2008; Chen et al., 
2009). Hence, it is necessary to understand 
the pathogenesis of mitochondrial defect in 
type 2 neuropathy diabetes.  
 
DIAGNOSTIC CHALLENGES   
Diagnosis of neuropathy diabetes can be 
difficult to determine. It highly under 
diagnosed both by endocrinologists as well 
as other physicians because its symptoms 
can be subclinical and not interfere with 
daily living. However, diagnosed based on 
the symptoms (numbness, tingling, or pain 
in feet, indigestion, nausea, or vomiting, 
diarrhea or constipation, problems with 
urination, dizziness) patient medical history 
and physical exam (Aristidis et al., 2008). 
Diagnostic procedure includes assessment 
of muscle strength, tone, tendon reflexes, 
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sensitivity to touch, temperature and 
vibration. Light touch perception have been 
evaluated by using a specifically calibrated 
devices (Semmes Weinstein (SWMF) 10- g 
in sizes ranging from 1.65 to 6.65). Vibration 
perception has been measured (Vibration 
by on/off (VO/O) with a 128-Hz tuning 
fork or less commonly range from 64 to 256 
Hz tuning forks. Electrophysiologic 
studies/ Nerve conduction studies (NCS) 
measures shows how quickly the nerves in 
your arms and legs conduct electrical 
signals. Quantitative sensory testing is used 
to assess how the nerves respond to 
vibration and changes in temperature. 
Biothesiometry, Tip-therm temperature 
discriminator, superficial pain sensation 
(SPS) have been used for measuring the 
vibration perception threshold (VPT) 
(Rayaz, 2008; Broedl and Goke, 2006; Kinga 
et al., 2006). Molecular levels diagnoses are 
available only for testing the inherited 
neuropathy (Suter and Scherer, 2003; Broedl 
and Goke, 2006). Mitochondrial study can 
support to find out the accurate diagnostic 
route for neuropathy diabetes additionally 
it can provides prognostic information, near 
future which may be important for choice 
of the therapies (http://www.cmtausa.org/ 
images/docs/AthenaTesting.pdf).  
 
DIABETIC NEUROPATHY THERAPY   
Treatment for neuropathy diabetes depends 
on symptoms and type of neuropathy 
complication. A large number of 
therapeutic agents have been proposed for 
the management of painful symptoms. 
However, diabetic neuropathy therapy can 
be classified into three types such as 
preventive, specific and symptomatic 
therapies (Geeta and Neera, 2007). The 
preventative therapy appears to be an 
association between polyneuropathy and 
predominantly painful polyneuropathy and 
abnormal glucose metabolism (Alberti and 
Zimmet, 1998). The valuable and premature 
treatment of hyperglycemia is an important 
factor in delaying the series of neuropathy 
(Maser et al., 1989). The specific therapy 
depends on the type of neuropathy the 
patient presents. But therapy options 
currently limited to symptomatic 
management while other specific therapy 
like drugs for nerve regeneration are still 
under experimental level. This specific 
therapy for diabetic neuropathy had proved 
to be disappointing (Elizabeth et al., 2009). 
A few specific therapies are aldose 
reductase inhibitors (ARI) are a class of 
medications that block the breakdown of 
glucose by specific metabolic pathway 
(polyol pathway) and potentially slow or 
reverse progression of neuropathy. ARI 
such as alrestatin, sorbinil, zenarestat, 
tolrestat, ponalrestat, zopolrestat and 
epalrestat are presently in use (Katrak, 
2004; Mary and Nancy, 2008). Natural and 
semi-synthetic Gangliosides are used to 
enhance the axonal regeneration and 
maturation in the early stages of 
neuropathy diabetes (Maser et al., 1989). 
Gama linoleic acid is the best supplements, 
it gives beneficial effect to the diabetic 
neuropathy patient (Chalk et al., 2007).  
Nerve growth factors such as insulin-like 
growth factor-1, acetyl-L-carnitine 
(ALCAR), recombination human nerve 
growth factor (rhNGF) may helpful for 
treating the neuropathy diabetes. Various 
other nerve growth factors are also under 
evaluation (Stuart, 2002; Windebank and 
Feldman, 2001). The symptomatic therapy 
is mainly focused on pain control. Pain 
management is pivotal role in neuropathy 
diabetes. An appropriate pharmacologic 
approaches act at different levels of 
neuroaxis in the axis of central nerves 
system and obliging for the management of 
neuropathic pain (Windebank and 
Feldman, 2001).   
Conventional remedies are highly 
significant and decrease the pain more 
effectively. Pharmacologic treatment 
therapy reduces the pain immediately but 
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does not eliminate it. There are several 
medications like duloxetine, pregabalin, 
tramadol, gabapentin are used for treating 
the neuropathy diabetes and also have been 
approved by the FDA. Initially, tricyclic 
antidepressants have been used for 
decreasing painful neuropathy symptoms 
but in recent times, these drugs are replaced 
in clinical use in most parts of the world by 
newer antidepressants such as the selective 
serotonin reuptake inhibitors and serotonin 
norepinephrine reuptake inhibitors to 
reduce the diabetic neuropathy pain and to 
increase the extracellular level of the 
neurotransmitter serotonin. However, these 
drugs typically have few side effects 
because these drugs are dosage dependent 
(Jeong et al., 2011; Llewelyn, 2003; Jin et al., 
2008). Anticonvulsants drugs have been 
used for neurological surgery pain control 
and also used to treat trigeminal neuralgia 
(Llewelyn, 2003). Antiepileptic drugs are 
used as a first line treatment for painful 
neuropathy (Jin et al., 2008). Opioids drugs 
reduces the perception of pain, decreased 
reaction to pain as well as increased pain 
tolerance these drugs have been used for 
the treatment of neuropathy diabetes. N 
methyl D aspartate agonists (NMDA) drugs 
are the attractive target for treatment of 
chronic neuropathic pain 
(http://www.newyorkbuyersclub.org/reso
urces/recommended-reading-files/24-
NEUROPATHY.pdf). The American 
Diabetes Association recommends using 
tricyclic antidepressant as first line and 
followed by anticonvulsant and then use of 
opioids or tramadol. Tricyclic 
antidepressant should not be used in 
patient with cardiac disease and elderly 
peoples which give advisory effect to the 
patient. In general almost all the drugs have 
beneficial effective against the diabetic 
neuropathy and as well as side effects like 
sedation, constipation, drossiness, 
respiratory depression etc (Boulton et al., 
2005; Llewelyn, 2003).   
 
SIGNIFICANCE OF ALTERNATIVE 
THERAPIES  
Use of alternative therapies is the safe and 
secure form of treatment. Hence scientists 
and medical practitioners are focused on 
the search of treatment for the several 
diseases including neuropathy diabetes in 
the field of ayurveda, homeopathy and 
siddha etc., as an alternative management. 
The number of alternative medication may 
also been recommended or prescribed for 
treating the neuropathy diabetes, these 
treatments maintain the sugar level and 
reduce the pain (Ertas et al., 1998; Bellavite 
et al., 2005; Kranthi and Vardhan, 2009; 
Lynda, 2005). Alternative therapies 
maintain the nerve restoring the sensation 
in feet and keep the sugar levels under 
control without causing any side effects. It 
can perform a beneficial function like 
scavenge the free radicals to eliminate 
oxidative stress in mitochondria, some of 
natural compound like antioxidant 
(Coenzyme Q, lipoic acid, α- tocopherol, 
glutathione), cofactors and their precursors 
(lipoic acid, B vitamins) which care for the 
mitochondria from oxidative damage and 
improve mitochondrial function. The 
Indian traditional herbs are auto regulatory, 
self healing medicine and supports to 
eliminate the disease from root causes 
(Bellavite et al., 2005). Proper diet 
management is a brilliant means of 
controlling or managing the neuropathy 
diabetes (www.ncdiabetes.org). The diet 
most often recommended are vegetables, 
(better gourd, string beans, carrot, radish, 
onion, garlic) high fiber content foods 
(cucumber, legumes, whole grain cereals, 
brewer’s yeast, peanuts) non vegetarian 
foods includes eggs, fish and poultry meat, 
feed supplements like vitamins (B,C and E ) 
and selected fruits supports the better 
neuropathy diabetes management (Lynda, 
2005; Prabhu et al., 2012; Ezekiel, 2009).  
Apart from the siddha, Ayurveda, 
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homeopathy relaxation technique like yoga 
and exercise are also pivotal role for the 
proper management of blood glucose levels 
and may reduce neuropathic pain and even 
prevent the neuropathy diabetes. Yoga is a 
traditional Indian psychological spiritual 
exercise regimen that has been studied for 
several decades for management of several 
diseases including diabetes (Broedl and 
Goke, 2006). Yoga and meditation which 
connects our body and mind reduces stress 
level and help nerve signals travel properly. 
It has great effect on the pancreas and other 
glands such as adrenal, thyroid etc., Specific 
asanas like surya namaskar, bhujangasana, 
dhanurasana, shalabhasana trikonasana, 
tadasana, sukhasana, padmasana, 
bhastrika, pranayama, shavasana are a 
number of recommended asana for 
neuropathic diabetes patients (Lynda, 2005; 
Gupta et al., 2006; Prabhu et al., 2012; Health 
Administrator). Specifically, focused 
breathing (Pranayama) keeps our and mind 
to reduce the stress (Khattab et al., 2007). 
Hence yoga, meditation and exercise are 
very essential to manage neuropathy 
diabetes, these practices stimulates the 
mitochondrial biogenesis by increasing 
gene expression of PGC-1, NRF-1, TFAM 
(Toledo et al., 2007). Endurance exercise 
increase mitochondrial enzyme activity and 
manage the blood glucose level (Trenell et 
al., 2008; Morrato et al., 2007; Toledo et al., 
2007). Acupuncture is another alternative 
medical practices for neuropathy diabetes it 
act on pancreas to enhance insulin synthesis 
and accelerate the utilization glucose and 
resulting in maintenance of blood sugar 
level. It is an alternative to conventional 
medical treatment of neuropathy diabetes 
(Irnich and Winnklmeier, 2002; Jiang et al., 
2006). Transcutaneous electronic nerve 
stimulation (low voltage electrical 
frequency at 50Hz) is another alternative 
therapy used for neuropathy pain relief. 
Effective alternative management practices 
includes regular exercise, suitable yoga, 
meditation, planned diet and any one of 
medication which fits to the biological 
systems without having side effects to 
manage the neuropathy diabetes.  
 
CONCLUSION  
Uncontrolled glucose regulation is widely 
recognized as the causes like between 
diabetes and its associated disease, 
including neuropathy diabetes. Several 
combination of factors contributes to cause 
the neuropathy diabetes are autoimmune 
response, genetics factors, lifestyle changes, 
drugs, alcohol abuse, smoking etc. In 
genetically, mitochondrial dysfunction also 
plays a role in cause of neuropathy 
diabetes. Impairment of OXPHOS system, 
dysfunction and oxidative stress in 
mitochondria may cause diabetes and its 
neuropathy complication. Present, 
diagnostic protocol is depending on clinical 
symptom, medical history and physical 
examination. However, there is need to 
study the molecular level diagnosis for 
early detection of neuropathy diabetes. 
Mitochondrial research in this area is 
essential to support diagnostic procedure 
near future. Currently there is no effective 
disease modifying treatment available for 
neuropathy diabetes. Moreover, the 
development of better treatment and novel 
preventive strategies for type 2 neuropathy 
diabetes is the matter of great urgency to 
provide patients and their family with 
prognostic advice. Numbers of 
conventional therapies have been used to 
maintain the blood sugar and control of 
neuropathy pain, however these medicines 
have both control and side effects. 
Nowadays, alternative treatment is the one, 
mostly followed by the people to avoid the 
side effects. It can be used either first or 
after controlling disease with conventional 
medicine to eliminate the disease from the 
root cause or as a preventive medicine. 
Herbal medicine, natural antioxidant, 
nutritional supplement supports for 
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reduces ROS, stimulate the mitochondrial 
biogenesis, prevent the oxidative damage 
and improve mitochondrial function. The 
aim of the therapeutic strategies is to 
preserving the mitochondrial structure and 
function could be beneficial treatment for 
neuropathy diabetes. Yoga, meditation and 
exercise reduces stress level, help nerve 
signals to travel properly and also it 
stimulates the mitochondrial biogenesis, 
increase mitochondrial enzyme activity. 
Hence sufficient scientific evidence is not 
available in this area of mitochondrial 
potential therapy to apply such controlling 
measures in the cause of neuropathy 
diabetes. Researches, physician should to 
focus on mitochondria potential therapy in 
the field of alternative medicines, will be 
the helpful way to suggest safer treatment 
to neuropathy diabetes. In our 
understanding, along with appropriate 
medications, relaxation technique like 
exercise, yoga, meditation, proper diet 
regulation and right feed supplements 
confer better results to the neuropathy 
diabetes.      
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